The impact of carvedilol on plasma cytokines and clinical efficacy in patients with chronic congestive heart failure
10.3760/cma.j.issn.1008-6706.2013.19.043
- VernacularTitle:卡维地洛对慢性充血性心力衰竭患者血浆炎性细胞因子及临床疗效的影响
- Author:
Jianming LAN
;
Shudong XIA
- Publication Type:Journal Article
- Keywords:
Heart failure,congestive;
Cytokines;
Carvedilol
- From:
Chinese Journal of Primary Medicine and Pharmacy
2013;20(19):2976-2978
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the impact of carvedilol on plasma cytokines in patients with chronic congestive heart failure(CHF) and its efficacy analysis.Methods 72 hospitalized patients with CHF were randomly divided into observation group and control group.The two groups were given standard therapy after admission.The observation group were given addition of carvedilol with an initial dose of 3.125mg,2 times daily,gradually increasing amount until the maintenance dose of 25mg,2 times daily for 12 weeks.Results After 12 weeks of treatment,plasma TNF-α,IL-1 and IL-6 in both groups were significantly decreased than before (t =3.02,3.17,2.97,2.26,2.25,2.21,all P ＜ 0.05) and the decline in the observation group was more significant than those in the control group(t =2.32,2.35,2.29,all P ＜ 0.05);The total clinical efficiency in the observation group(94.44％) was significantly higher(77.78％)(x2 =4.18,P ＜ 0.05),and there were no significant adverse drug reactions during treatment in both groups.During 1-year follow-up after treatment,re-hospitalization rate in the observation group (61.11％) was significantly lower than that in the control group (36.11％) (x2 =4.50,P ＜ 0.05),but there was no statistically significant difference in mortality between two groups (x2 =0.26,P ＞ 0.05).Conclusion Carvedilol is a safe and effective drug for the treatment of CHF,which can lower plasma cells factor TNF-α,IL-1 and IL-6 levels,reduce patient re-hospitalization rates,and help to improve the patients' prognosis.
